He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company (read more in his DeviceTalks speaker bio).
Medtronic has more than $500 million in venture investments, managed by Neustaedter’s group and others in the company. Every investment handled by his group requires two things.
Get the full story at our sister site, Medical Design & Outsourcing.
David Neustaedter is Medtronic’s VP of venture investments [Photo courtesy of Medtronic]
A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT).He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.)
Medtronic has more than $500 million in venture investments, managed by Neustaedter’s group and others in the company. Every investment handled by his group requires two things.
“The first is we expect top-tier institutional venture returns on investments, and we’ve pulled that off for the last 14 years. So we’re sticking with that,” he said. “And then the second is really strategic fit with Medtronic. The usual form for that is, ‘Is this a company th…